Video Roundup: Young Guns of Wall Street

By CNBC.com Staff
Friday, 13 Jul 2007 | 4:16 PM ET

CNBC's Young Guns series profiling the top analysts, traders and money managers on Wall Street under 35 years old. Squawk on the Street's Erin Burnett and Mark Haines talk to these rising stars of the investment world about what makes them the best at what they do.

Young Guns
Highlighting the young guns on Wall Street, with Minyoung Sohn, Janus Adviser Fundamental Equity portfolio manager and CNBC's Erin Burnett

Best of the Best

Min Sohn manages two five-star funds for Janus -- the Fundamental Equity and Growth & Income funds. Sohn picks his stocks with the shrewd and prudent wisdom of a seasoned investor, working closely with his research team and sometimes making some difficult calls, especially with refiner Valero: "We're very impressed by their focus on improving both balance sheet and capital efficiency," he says. Find out why he thinks the recent subprime mess may make Fannie Mae a good bet.

Young Guns
Highlighting the best of the best on Wall Street, with Marc Pasuco, Apache Trading LLC CEO/head trader and CNBC's Erin Burnett

Going With Your Gut

ETF trader, Marc Pasuco of Apache Trading has something of a reputation for unbelievable discipline in all market conditions. Pasuco himself says people in the ETF game "either have it, or they don't."

Hailed by Trader Monthly's "Thirty Under Thirty," Pasuco backs up his braggadocio claiming now that ETF spreads are so tight "you really have to have a niche for the market." Pasuco also explains why he thinks the tax advantages of ETFs make a better investment than mutual funds.

Young Guns
Meeting the rising stars of Wall Street, with Maria Grant, Goldman Sachs chief options strategist and CNBC's Mark Haines

Options On Options

Maria Grant, chief options strategist for Goldman Sachs, took great pains to demystify the complex and somewhat intimidating world of options trading. She says those who have learned complex options strategies may be surprised to discover that "the bulk of what actually trades is actually very simple."

There's nothing confusing about her track record. "We had 35% growth last year alone and the market has been growing at a greater than 25% clip over the past few years" says Grant.

Young Guns
One of this week's top five among analysts, traders and money managers, with Brian Tunick, JP Morgan specialty retail analyst and CNBC's Erin Burnett

No One Hit Wonder

Specialty retail analyst Brian Tunick of JPMorgan explains his strategy for sizing up hit driven products, such as toys based on film characters like Shrek.

"The trend is your friend, so if you have a stumble in the first quarter, usually you have inventory levels that are too high, earnings are at risk so it's better off to wait for these companies to clear out inventories and come back a couple of quarters later." Turnick says another reason for his success is that he avoids falling in and out of love with certain stocks.

Among his picks are Abercrombie and Fitch, Hot Topic, and Federated (soon to be renamed Macys).

Disclosure note: Neither Tunick, the firm nor members of his family own shares but JPMorgan does do business with companies covered by its analysts.

Best of the Best
Highlighting the young gun traders under the age of 35, with Mark Schoenebaum, Bear Stearns

Taking The Pulse of Biotech

Mark Schoenebaum, Bear Stearns' biotechnology expert, has been named the best in his field by "Institutional Investor" for two years in a row.

He is cautious in the short term, but bullish long term. Schoenebaum says it has been a tough year for the big names in the field and that pricing pressure and concerns about a longer FDA approval process headwinds for the sector.

Long term he is bullish because valuations are very low and there's the potential for a new product cycle.

As for Genentech, whose stock has slumped despite second-quarter outstanding earnings, Schoenebaum says "the business is very healthy," but admits that "third-quarter results are tougher to predict."

Disclosure note: Schoenebaum and members of his family own shares of Genentech. Bear Stearns and/or its affiliates have done business with the company, as well as other biotech firms, in the past 12 months.

  Price   Change %Change


Contact U.S. News


    Get the best of CNBC in your inbox

    › Learn More

Don't Miss

U.S. Video

  • Mad Money's Jim Cramer discusses Micron Technology and how the company gained control over inventory issues. The bears expect the company's history to repeat itself, but Cramer says this time, it feels different.

  • In this excerpt from a live CNBC interview, Warren Buffett explains why it's extremely unusual for a company's directors to vote against executive compensation plans.

  • Mad Money host Jim Cramer says shareholder activism works for every shareholder, and offers his take on the Valeant/Bill Ackman bid to acquire Allergan. The market is better off for these efforts, he says.